Skip to main content

Table 3 ORRs of clinical symptoms in the IFNα1b group and the control group after days of treatment (%)

From: Efficacy and safety of aerosol inhalation of recombinant human interferon α1b (IFNα1b) injection for noninfluenza viral pneumonia, a multicenter, randomized, double-blind, placebo-controlled trial

Group

FAS

ORR

PPS

ORR

n

n

Control group

87

65.51 ± 35.59

82

66.26 ± 35.65

IFNα1b group

76

76.87 ± 25.15

69

77.16 ± 24.19

P

0.037

 

0.033

 
Back to article page

Journal of Inflammation

ISSN: 1476-9255

Contact us